RBPJL and esophageal squamous cell carcinoma: We report for the first time that RBPJL (p.P476S) promotes tumor growth in oesophageal squamous cell carcinoma (ESCC) and inhibits the efficacy of anti‐PD‐1 therapy by blunting T‐cell responses.